Gut Resilience and Immune Support

By: Yekta Dowlati, PhD

Maintaining gut homeostasis is foundational to overall health, with increasing research emphasizing the gut microbiota’s pivotal role in immunity, digestion, and systemic well-being. Modern lifestyle factors such as poor diet, antibiotic exposure, infections, and aging can disrupt this microbial balance, creating opportunities for health deterioration.

Probiotics are defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.”¹ In contrast, prebiotics are “substrates that are selectively utilized by host microorganisms, conferring a health benefit.”² When combined, these agents form synbiotics—defined as “a mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host.” They have emerged as a targeted strategy to support gut and immune function by reinforcing microbial diversity and metabolic activity.³

This review highlights clinical evidence supporting two clinically validated, spore-forming probiotic strains—Bacillus coagulans SNZ 1969® and Bacillus subtilis DE111®—in conjunction with inulin-type fructans from chicory root, a widely studied prebiotic fiber.

Resilient Probiotic Strains: Bacillus Species

Bacillus species are distinguished by their ability to form resilient endospores, allowing them to withstand environmental stressors such as heat, acidity, and processing. This unique characteristic supports their survival through gastric transit and enables precise delivery to the small intestine, where they germinate in response to favorable conditions. The spore-based nature of these strains contributes to consistent efficacy in promoting gut health.⁴

Both Bacillus coagulans SNZ 1969® and Bacillus subtilis DE111® are classified as Generally Recognized as Safe (GRAS) for use in food and dietary supplements, a designation supported by toxicological and clinical safety data. This status allows their incorporation into evidence-based formulations for digestive, immune, and metabolic support.

Bacillus coagulans SNZ 1969®: Gastrointestinal and Microbiome Benefits

Clinical trials support the efficacy of B. coagulans SNZ 1969® in promoting bowel regularity and reducing GI discomfort:

• • In a randomized, placebo-controlled 8-week study with 80 healthy adults experiencing occasional constipation, 1 billion CFU/day of B. coagulans SNZ 1969® significantly reduced colonic transit time and improved completeness of bowel movements. It also favorably modulated the gut microbiome.⁵
  • A separate 30-day trial in 60 adults with GI discomfort evaluated the impact of 2 billion CFU/day of B. coagulans SNZ 1969® using the Severity of Dyspepsia Assessment (SODA) scale. Compared to placebo, treatment significantly improved total SODA scores and subscores for pain intensity, non-pain symptoms, treatment satisfaction, and sour taste symptoms.⁶
  • Additional evidence from a study in 92 adults with functional GI symptoms showed that 1 billion CFU/day improved GI discomfort and health-related quality of life.⁷

These outcomes underscore the ability of B. coagulans SNZ 1969® to promote digestive comfort and regularity through both microbial and host-mediated pathways.

Bacillus subtilis DE111®: Immune and Inflammatory Support

B. subtilis DE111® has also demonstrated clinical relevance in diverse populations:

• • In a study of 102 day-care attending children, 1 billion CFU/day of B. subtilis DE111® improved gut microbiome diversity, reduced the Firmicutes-to-Bacteroidetes ratio, and supported normal bowel movements and immune function.^8,9
  • A 12-week trial in 25 collegiate male athletes showed that supplementation significantly reduced TNF-α concentrations during periods of academic and physical stress.¹⁰
  • In a 90-day study of 50 healthy adults with occasional constipation and/or diarrhea, B. subtilis DE111 (1 billion CFU/day) increased the frequency of normal stool types compared to placebo (43.1% vs. 35.4%).¹¹

• • A separate 4-week trial in 46 healthy adults supplemented with subtilis DE111 (1 billion CFU/day) demonstrated cardiometabolic benefits, including an 8 mg/dL reduction in total cholesterol and an 11 mg/dL decrease in non-HDL cholesterol.¹²

These findings position B. subtilis DE111® as a clinically viable probiotic with immune-modulating, anti-inflammatory, and metabolic support properties.

Chicory Root: A Functional Prebiotic Matrix

Chicory (Cichorium intybus) root contains inulin-type fructans—non-digestible fibers that serve as substrates for commensal bacteria in the colon. Once fermented by gut microbes, they yield short-chain fatty acids (SCFAs), which enhance barrier function, regulate inflammation, and modulate host metabolism.^13,14

Notably, chicory root exhibits bifidogenic effects. A systematic review of randomized controlled trials demonstrated that even low doses (≥3 g/day) of inulin-type fructans significantly increased Bifidobacterium abundance, contributing to a healthier microbial profile.¹⁵

Complementary Synbiotics: Mechanistic and Clinical Synergy

According to the ISAPP, complementary synbiotics are formulations that combine probiotics and prebiotics with independent health benefits.³ The synbiotic pairing of B. coagulans SNZ 1969® and B. subtilis DE111® with chicory-derived inulin-type fructans represents a science-backed solution for supporting gut health, immune resilience, and metabolic balance.

This synbiotic strategy may offer enhanced compliance due to formulation convenience, while delivering clinically substantiated benefits in promoting bowel regularity, reducing GI discomfort, modulating systemic inflammation, and enhancing microbial diversity.

References

1. 1. Hill C et al. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514.
   2. Gibson GR et al. Nat Rev Gastroenterol Hepatol. 2017;14(8):491-502.
   3. Swanson KS et al. Nat Rev Gastroenterol Hepatol. 2020;17(11):687–701.
   4. Cao J et al. J Funct Foods. 2020;64(1):103643.
   5. Kang S et al. Food Res Int. 2021;146:110428.
   6. Soman RJ et al. Int J Health Sci Res. 2022;12(3):253–264.
   7. Soman RJ et al. Int J Basic Clin Pharmacol. 2022;11(6):550–558.
   8. Slivnik MM et al. J Prob Health. 2020;8(4):225.
   9. Paytuvi-Gallart A et al. Benef Microbes. 2020;11(7):611–620.
   10. Townsend JR et al. Sports (Basel). 2018;6(3):70.
   11. Cuentas AM et al. J Prob Health. 2017;5(4).
   12. Trotter RE et al. Benef Microbes. 2020;11(7):621–630.
   13. Cherbut C. Br J Nutr. 2002;87 Suppl 2:S159–S162.
   14. Koh A et al. Cell. 2016;165(6):1332–1345.
   15. Nagy DU et al. Crit Rev Food Sci Nutr. 2023;63(33):12018-12035.